11:58 AM EDT, 06/17/2024 (MT Newswires) -- Charles River Laboratories ( CRL ) and Captain T Cell said Monday that they have entered into a plasmid DNA and retrovirus vector production program deal.

Captain T Cell will use plasmid and viral vector contract development and manufacturing organization services under Charles River's cell and gene therapy accelerator program, the companies said.

This will support Captain T Cell's preparation to manufacture a T cell receptor T cell therapy for solid tumor patients for a phase 1 trial, the companies added.

Price: 208.55, Change: -0.92, Percent Change: -0.44